It's How Medicine Should Be®


French German Italian Portuguese Russian

Extensive Stage Small Cell Lung Cancer Treatment Study

Clinical Trial Title: 
A phase III randomized, double-blind, placebo-controlled trial of pembrolizumab (MK-3475) in combination with etoposide/platinum (cisplatin or carboplatin) for the first-line treatment of subjects with extensive stage small cell lung cancer (KEYNOTE-604).
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Mary Jo Fidler, MD
Clinical Trial Protocol Description: 

The purpose of this study is to assess the safety and efficacy of pembrolizumab plus standard of care (SOC) chemotherapy (etoposide/platinum) in participants with newly diagnosed extensive stage small cell lung cancer who have not previously received systemic therapy for this malignancy.

During each 21-day cycle, participants receive pembrolizumab or placebo infusion plus etoposide infusion on days 1, 2 and 3, plus doctor’s choice of platinum infusion. Participants may receive study treatment for a maximum of up to about 3 years.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have a new diagnosis of small cell lung cancer (SCLC).
  • Have stage IV disease.
  • Have measurable lesions.

You will be excluded from the study if any of the following criteria apply to you:

  • Have received prior systemic therapy for the treatment of SCLC.
  • Have known central nervous system metastases and/or carcinomatous meningitis.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Lung and Chest Tumors
Contact Phone: 
(312) 563-3921
Contact Name: 
Emily Rubenstein, RN